^
Association details:
| Biomarker: | KRAS G12C |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | divarasib (RG6330) (KRAS G12C inhibitor) + migoprotafib (RLY-1971) (PTPN11 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
3327 / 5 - Discovery and characterization of the potent, allosteric SHP2 inhibitor GDC-1971 for the treatment of RTK/RAS driven tumors
Published date:
03/09/2022
Excerpt:
GDC-1971 in combination with the KRAS G12C covalent inhibitor GDC-6036 resulted in significant regressions at doses well below those required for single agent activity in a KRAS G12C-mutant NSCLC xenograft model.
